PPARγ agonist use and recurrence of atrial fibrillation after successful electrical cardioversion

Iwasaki, 2011, Atrial fibrillation pathophysiology: implications for management, Circulation, 124, 2264, 10.1161/CIRCULATIONAHA.111.019893 Gu, 2013, Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models, J Mol Cell Cardiol, 65, 1, 10.1016/j.yjmcc.2013.09.016 Alcaraz, 2011, Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion, Pacing Clin Electrophysiol, 34, 1241, 10.1111/j.1540-8159.2011.03125.x Barassi, 2012, Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function, Can J Cardiol, 28, 537, 10.1016/j.cjca.2012.02.014 Chao, 2012, Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes, Int J Cardiol, 156, 199, 10.1016/j.ijcard.2011.08.081 Xu, 2012, PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model, J Cardiovasc Electrophysiol, 23, 209, 10.1111/j.1540-8167.2011.02186.x Gu, 2011, Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus, Europace, 13, 1256, 10.1093/europace/eur131 Smit, 2012, Role of inflammation in early atrial fibrillation recurrence, Europace, 14, 810, 10.1093/europace/eur402 Almroth, 2009, Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study, Eur Heart J, 30, 827, 10.1093/eurheartj/ehp006 Tveit, 2007, Candesartan in the prevention of relapsing atrial fibrillation, Int J Cardiol, 120, 85, 10.1016/j.ijcard.2006.08.086